pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting vegfr2 activationpristimerin、三萜、抑制肿瘤血管生成,针对vegfr2激活.pdfVIP

Molecules 2012, 17, 6854-6868; doi:10.3390/molecule OPEN ACCESS molecules ISSN 1420-3049 /journal/molecules Article Pristimerin, a Triterpenoid, Inhibits Tumor Angiogenesis by Targeting VEGFR2 Activation Xianmin Mu 1,2, Wei Shi 3, Lixin Sun 1, Han Li 1, Zhenzhou Jiang 1,* and Luyong Zhang 1,4,* 1 Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing 210009, Jiangsu, China; E-Mails: cpumxm@ (X.M.); slxcpu@126.com (L.S.); lihan@ (H.L.) 2 The Secondary Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, China 3 Department of New Drug Screening, Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd, Nanjing 210042, Jiangsu, China; E-Mail: shiwei411@ 4 Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, Nanjing 210009, Jiangsu, China * Authors to whom correspondence should be addressed; E-Mails: jiangcpu@ (Z.J.); lyzhangchina@ (L.Z.); Tel./Fax: +86-25 Received: 9 April 2012; in revised form: 11 May 2012 / Accepted: 15 May 2012 / Published: 5 June 2012 Abstract: Pristimerin is a triterpenoid isolated from Celastrus and Maytenus spp. that has been shown to possess a variety of biological activities, including anti-cancer activity. However, little is known about pristimerin’s effects on tumor angiogenesis. In this study, we examined the function and the mechanism of this compound in tumor angiogenesis using multiple angiogenesis assays. We found that pristimerin significantly reduced both the volum